Delphi Consensus on Migraine Diagnosis and Treatment Guidelines in Asia-Pacific

A 2026 Delphi consensus study by Charles Hua Chiang Siow, involving 14 headache specialists from seven Asia-Pacific countries. The study reached consensus on 12 out of 21 statements regarding the application of ICHD-3 diagnostic criteria and the use of anti-CGRP monoclonal antibodies for migraine management. The document is a 34.5 KB text file summarizing the methodology, results, and conclusions of the expert panel.

Use Cases

• Analyze expert consensus on migraine diagnostic criteria based on reported usage of ICHD-3 guidelines.
• Study clinician-reported factors influencing anti-CGRP mAb treatment selection based on efficacy, safety, and tolerability data.
• Investigate regional treatment patterns for migraine-associated symptoms like neck pain and dizziness based on survey results.
• Examine expert opinions on pediatric use of migraine therapies based on consensus statements regarding age groups.

Strengths

• Documented 100% participation rate in both survey rounds among the 14 specialist participants.
• Provides specific consensus percentages, such as 93% of participants using ICHD-3 criteria and 86% endorsing anti-CGRP mAbs for unmet needs.
• Clear methodology described using a modified-Delphi method with a defined 75% consensus threshold.

Limitations

• Row count is unknown, which may limit suitability assessment for quantitative analysis.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a 34.5 KB text document, representing a very limited scope focused on summary findings rather than raw survey data.

Provenance

Source

figshare, authored by Charles Hua Chiang Siow.

Collection Method

Modified-Delphi method involving two survey rounds and a virtual scientific meeting.

Time Range

Study conducted circa 2026.

Freshness

Last updated 2026-05-28 04:36:06; freshness should be verified.

Geography

Asia-Pacific region, with participants from seven countries.